Rx AOD9604

AOD9604 References: Published Clinical and Preclinical Citations

AOD9604 Published References

All citations used across this site are listed below. Every AOD9604 citation is drawn from the peer-reviewed record or from primary regulatory and anti-doping source documents. DOIs and PubMed URLs are provided where available. See published references and citations for the complete list.

  1. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity and Related Metabolic Disorders. 2001;25(10):1442-1449. ↗
  2. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. ↗
  3. Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. Journal of Molecular Endocrinology. 2000;25(3):287-298. ↗
  4. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. ↗
  5. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. [IGF-1 non-elevation data] ↗
  6. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. [Glucose tolerance data] ↗
  7. Metabolic Pharmaceuticals. Obesity drug codenamed AOD9604 highly successful in trials (Phase IIa METAOD005 results). News-Medical.net. 2004 Dec 16. ↗
  8. Metabolic Pharmaceuticals (METAOD006 study group). The effect of AOD9604 on weight loss in obese adults: Results of a randomized, double-blind, placebo-controlled, multicenter study. 2008. ↗
  9. More MI, Kenley D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism. 2014;4(3):116-126. [Chronic toxicology and NOAEL data] ↗
  10. More MI, Kenley D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism. 2014;4(3):116-126. [Pig pharmacokinetic data] ↗
  11. Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of Clinical and Laboratory Science. 2015;45(4):426-432. ↗
  12. AOD 9604 Peptide Research Overview: Chondrocyte Extracellular Matrix Studies. Secondary synthesis of unpublished/presented preclinical chondrocyte data. 2015. ↗
  13. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. [Anti-drug antibody data] ↗
  14. Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. 2015;7(5):449-458. ↗
  15. Thevis M, Thomas A, Schanzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics. 2014;11(6):663-674. ↗
  16. Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clinical Pharmacology and Therapeutics. 2010;87(6):652-662. ↗
  17. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. [Regulatory context and discontinuation rationale] ↗
  18. More MI, Kenley D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism. 2014;4(3):116-126. [IV half-life and pharmacokinetics] ↗
  19. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity and Related Metabolic Disorders. 2001;25(10):1442-1449. [Lean-mass preservation data] ↗
  20. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. [No withdrawal effects data] ↗
  21. Metabolic Pharmaceuticals. Obesity drug codenamed AOD9604 highly successful in trials (Phase IIa METAOD005 results — secondary metabolic markers). News-Medical.net. 2004 Dec 16. ↗
  22. U.S. Food and Drug Administration. December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. 2024. ↗
  23. World Anti-Doping Agency. 2026 Prohibited List. WADA Executive Committee approved September 11, 2025. ↗
  24. Liao Y, et al. Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis (Systematic Review). Cartilage. 2024. ↗